文献速递基础与转化研究临床试验与 GCP

CICAFAST:比较由胎儿成纤维细胞和角质形成细胞组成的生物敷料与传统的分厚皮片供区敷料:一项随机对照试验

CICAFAST: comparison of a biological dressing composed of fetal fibroblasts and keratinocytes on a split-thickness skin graft donor site versus a traditional dressing: a randomized controlled trial.
PubMed 文献 · Trials · 2019-10-28

本研究为随机对照试验,在分厚皮片移植供区比较由胎儿成纤维细胞和角质形成细胞接种于胶原基质的新型生物敷料与常规敷料。主要目的是验证该生物敷料能否缩短愈合时间、减轻疼痛并改善瘢痕外观,同时可能减少镇痛药物使用和病假时间。

要点

  • 在分厚皮片供区比较生物敷料与常规敷料愈合效果。
  • 生物敷料含胎儿成纤维细胞和角质形成细胞及胶原基质。
  • 评估指标包括愈合时间、疼痛、瘢痕外观及镇痛药使用。

核心结论

  • 该临床试验旨在建立基于再生敷料的分厚皮片供区创面愈合新策略。

研究设计与样本

  • 随机对照试验,在同一患者的分厚皮片供区比较新型生物敷料与常规治疗。

主要发现

  • 原文未报告研究结果。

临床怎么用

  • 作者希望该生物敷料能加速愈合、改善瘢痕外观并减轻疼痛,从而改善皮肤移植的治疗条件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Wound repair is one of the most complex biological processes of human life. Allogeneic cell-based engineered skin substitutes provide off-the-shelf temporary wound coverage and act as biologically active dressings, releasing growth factors, cytokines and extracellular matrix components essential for proper wound healing. However, they are susceptible to immune rejection and this is their major weakness. Thanks to their low immunogenicity and high effectiveness in regeneration, fetal skin cells represent an attractive alternative to the commonly used autologous and allogeneic skin grafts. METHODS/DESIGN: We developed a new dressing comprising a collagen matrix seeded with a specific ratio of active fetal fibroblasts and keratinocytes. These produce a variety of healing growth factors and cytokines which will increase the speed of wound healing and induce an immunotolerant state, with a slight inflammatory reaction and a reduction in pain. The objective of this study is to demonstrate that the use of this biological dressing for wound healing at the split-thickness skin graft (STSG) donor site, reduces the time to healing, decreases other co-morbidities, such as pain, and improves the appearance of the scar. This investigation will be conducted as part of a randomized study comparing our new biological dressing with a conventional treatment in a single patient, thus avoiding the factors that may influence the healing of a graft donor site. DISCUSSION: This clinical trial should enable the development of a new strategy for STSG donor-wound healing based on a regenerative dressing. The pain experienced in the first few days of STSG healing is well known due to the exposure of sensory nerve endings. Reducing this pain will also reduce analgesic drug intake and the duration of sick leave. Our biological dressing will meet the essential need of surgeons to "re-crop" from existing donor sites, e.g., for thermal-burn patients. By accelerating healing, improving the appearance of the scar and reducing pain, we hope to improve the conditions of treatment for skin grafts. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03334656 . Registered on 7 November 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Poinas A, Perrot P, Lorant J, et al. CICAFAST: comparison of a biological dressing composed of fetal fibroblasts and keratinocytes on a split-thickness skin graft donor site versus a traditional dressing: a randomized controlled trial. Trials. 2019. PMID: 31661012. doi:10.1186/s13063-019-3718-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。